Novartis got a reprieve last week when the U.S. Patent and Trademark Office upheld a patent on its multiple sclerosis blockbuster Gilenya. Now, the Swiss pharma intends to use that win in court ...
Novartis International AG / New analysis indicates that Novartis drug Gilenya shows significant early effect on reducing brain volume loss at 6 months . Processed and transmitted by Thomson Reuters ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results